share_log

United Therapeutics | 10-Q: Q2 2024 Earnings Report

United Therapeutics | 10-Q: Q2 2024 Earnings Report

美國聯合醫療 | 10-Q:2024財年二季報
美股SEC公告 ·  2024/07/31 10:34

牛牛AI助理已提取核心訊息

United Therapeutics reported strong Q2 2024 financial results with total revenues increasing 20% to $714.9 million, driven by robust growth in Tyvaso product sales. Total Tyvaso revenues, including Tyvaso DPI and nebulized Tyvaso, grew 25% year-over-year to $398.2 million, benefiting from increased patient adoption and price increases.Operating income remained stable at $319.9 million compared to $313.4 million in Q2 2023, despite higher operating expenses. Research and development expenses increased 57% to $139.6 million, while selling, general and administrative expenses rose 37% to $177.6 million, primarily due to increased legal expenses and personnel costs.The company maintained a strong financial position with $4.3 billion in cash and investments as of June 30, 2024. During the quarter, United Therapeutics executed a $1 billion accelerated share repurchase program and reduced its credit facility balance to $500 million. The company continues to advance its pipeline, including Phase 3 trials for nebulized Tyvaso in IPF and PPF indications, as well as organ manufacturing initiatives.
United Therapeutics reported strong Q2 2024 financial results with total revenues increasing 20% to $714.9 million, driven by robust growth in Tyvaso product sales. Total Tyvaso revenues, including Tyvaso DPI and nebulized Tyvaso, grew 25% year-over-year to $398.2 million, benefiting from increased patient adoption and price increases.Operating income remained stable at $319.9 million compared to $313.4 million in Q2 2023, despite higher operating expenses. Research and development expenses increased 57% to $139.6 million, while selling, general and administrative expenses rose 37% to $177.6 million, primarily due to increased legal expenses and personnel costs.The company maintained a strong financial position with $4.3 billion in cash and investments as of June 30, 2024. During the quarter, United Therapeutics executed a $1 billion accelerated share repurchase program and reduced its credit facility balance to $500 million. The company continues to advance its pipeline, including Phase 3 trials for nebulized Tyvaso in IPF and PPF indications, as well as organ manufacturing initiatives.
美國聯合醫療發佈了強勁的2024年第二季度業績,總收入增長了20%,達71490萬,得益於Tyvaso產品銷售的強勁增長。包括Tyvaso DPI和霧化Tyvaso在內的Tyvaso總收入同比增長25%,達到39820萬,受益於患者採用率的提高和價格上漲。儘管營業費用有所上升,營業收入仍保持穩定,爲31990萬,與2023年第二季度的31340萬相比。研發費用增長了57%,達到13960萬,而銷售、一般及行政費用上漲了37%,達17760萬,主要由於法律費用和人事成本的增加。截至2024年6月30日,公司保持着強勁的財務狀況,現金和投資總額達到43億。在本季度, 美國聯合醫療實施了一項10億的加速股票回購計劃,並將其信貸設施餘額減少至50000萬。公司繼續推進其研發管線,包括霧化Tyvaso在特發性肺纖維化(IPF)和原發性肺纖維化(PPF)適應症的三期試驗,以及器官制造項目。
美國聯合醫療發佈了強勁的2024年第二季度業績,總收入增長了20%,達71490萬,得益於Tyvaso產品銷售的強勁增長。包括Tyvaso DPI和霧化Tyvaso在內的Tyvaso總收入同比增長25%,達到39820萬,受益於患者採用率的提高和價格上漲。儘管營業費用有所上升,營業收入仍保持穩定,爲31990萬,與2023年第二季度的31340萬相比。研發費用增長了57%,達到13960萬,而銷售、一般及行政費用上漲了37%,達17760萬,主要由於法律費用和人事成本的增加。截至2024年6月30日,公司保持着強勁的財務狀況,現金和投資總額達到43億。在本季度, 美國聯合醫療實施了一項10億的加速股票回購計劃,並將其信貸設施餘額減少至50000萬。公司繼續推進其研發管線,包括霧化Tyvaso在特發性肺纖維化(IPF)和原發性肺纖維化(PPF)適應症的三期試驗,以及器官制造項目。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 305

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。